U20 is responsible for human herpesvirus 6B inhibition of tumor necrosis factor receptor-dependent signaling and apoptosis

Journal of Virology

Volumn 86, Issue 21, 2012, Pages 11483-11492

  Kofod Olsen, Emil ^a   Ross Hansen, Katrine ^a,b   Schleimann, Mariane Høgsbjerg ^a   Jensen, Dea Kejlberg ^a   Møller, Janni Michelle Lund ^a   Bundgaard, Bettina ^a   Mikkelsen, Jacob Giehm ^a   Höllsberg, Per ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 8; CYCLOHEXIMIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN U20; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SERINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; IMMUNE EVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIRUS TRANSCRIPTION;

APOPTOSIS; CELL LINE; EPITHELIAL CELLS; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNE EVASION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRULENCE FACTORS;

HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 6B;

EID: 84869068662     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00847-12     Document Type: Article

References (49)

1. Abramoff MD, Magalhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophoton Int. 11:36-42.
2. Arbuckle JH, et al. 2010. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 107:5563-5568.
3. Cassiani-Ingoni R, et al. 2005. CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. Glia 52:252-258.
4. Chan FK, et al. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288:2351-2354.
5. Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T. 2007. Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J. Biol. Chem. 282:29284-29295.
6. Cole C, Barber JD, Barton GJ. 2008. The JPRED 3 secondary structure prediction server. Nucleic Acids Res. 36:W197-W201.
7. Combet C, Blanchet C, Geourjon C, Deléage G. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150.
8. Cuomo L, et al. 1998. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBVcarrying Burkitt lymphoma cells. J. Med. Virol. 55:219-226.
9. Dominguez G, et al. 1999. Human herpesvirus 6B genome sequence:coding content and comparison with human herpesvirus 6A. J. Virol.73:8040-8052.
10. Fotheringham J, et al. 2007. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med. 4:e180. doi:10.1371/journal.pmed.0040180.
11. Fotheringham J, Williams EL, Akhyani N, Jacobson S. 2008. Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J. Neuroimmune Pharmacol. 3:105-116.
12. Hall CB, et al. 2008. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 122:513-520.
13. Hong M, et al. 2006. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J. Cancer Res. Clin. Oncol. 132:1-8.
14. Hubacek P, et al. 2009. Prevalence of HHV-6 integrated chromosomally among children treated for acute lymphoblastic or myeloid leukemia in the Czech Republic. J. Med. Virol. 81:258-263.
15. Isegawa Y, et al. 1999. Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B. J. Virol. 73:8053-8063.
16. Josephs SF, et al. 1986. Genomic analysis of the human B-lymphotropic virus (HBLV). Science 234:601-603.
17. Kieser A. 2008. Pursuing different 'TRADDes': TRADD signaling induced by TNF-receptor 1 and the Epstein-Barr virus oncoprotein LMP1. Biol. Chem. 389:1261-1271.
18. Kofod-Olsen E, Ross-Hansen K, Mikkelsen JG, Hollsberg P. 2008. Human herpesvirus 6B U19 protein is a PML-regulated transcriptional activator that localizes to nuclear foci in a PML-independent manner. J. Gen. Virol. 89:106-116.
19. Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. 1991. Latent human herpesvirus 6 infection of human monocytes/macrophages. J. Gen. Virol. 72:1401-1408.
20. Krueger GR, Huetter ML, Rojo J, Romero M, Cruz-Ortiz H. 2001. Human herpesviruses HHV-4 (EBV) and HHV-6 in Hodgkin's and Kikuchi's diseases and their relation to proliferation and apoptosis. Anticancer Res. 21:2155-2161.
21. Lacroix A, et al. 2007. HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma. J. Med. Virol. 79:1349-1356.
22. Lee JM, et al. 2004. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. 78:12694-12697.
23. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. 2003. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18:655-664.
24. Li H, Kobayashi M, Blonska M, You Y, Lin X. 2006. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J. Biol. Chem. 281:13636-13643.
25. Luppi M, et al. 1999. Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. J. Virol. 73:754-759.
26. Lusso P, et al. 1988. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J. Exp. Med. 167:1659-1670.
27. Micheau O, Tschopp J. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
28. Okuno T, et al. 1989. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J. Clin. Microbiol. 27:651-653.
29. Oster B, Bundgaard B, Hollsberg P. 2005. Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells. J. Virol. 79:1961-1965.
30. Oster B, Hollsberg P. 2002. Viral gene expression patterns in human herpesvirus 6B-infected T cells. J. Virol. 76:7578-7586.
31. Oster B, Kofod-Olsen E, Bundgaard B, Hollsberg P. 2008. Restriction of human herpesvirus 6B replication by p53. J. Gen. Virol. 89:1106-1113.
32. Petersen B, Petersen TN, Andersen P, Nielsen M, Lundegaard C. 2009. A generic method for assignment of reliability scores applied to solvent accessibility predictions. BMC Struct. Biol. 9:51.
33. Petersen TN, Brunak S, Heijne GV, Nielsen H. 2011. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat. Methods 8:785-786.
34. Pollastri G, McLysaght A. 2005. Porter: a new, accurate server for protein secondary structure prediction. Bioinformatics 21:1719-1720.
35. Salahuddin SZ, et al. 1986. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234:596-601.
36. Schirmer EC, Wyatt LS, Yamanishi K, Rodriguez WJ, Frenkel N. 1991. Differentiation between two distinct classes of viruses now classified as human herpesvirus 6. Proc. Natl. Acad. Sci. U.S.A. 88:5922-5926.
37. Schneider-Brachert W, et al. 2004. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21:415-428.
38. Silins SL, Sculley TB. 1995. Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen EBNA-4. Int. J. Cancer 60:65-72.
39. Silva LC, Ortigosa LC, Benard G. 2010. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2:817-833.
40. Skaletskaya A, et al. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. U.S.A. 98:7829-7834.
41. Tsao EH, et al. 2009. Microarray-based determination of the lytic cascade of human herpesvirus 6B. J. Gen. Virol. 90:2581-2591.
42. Turcanova VL, Bundgaard B, Hollsberg P. 2009. Human herpesvirus-6B induces expression of the human endogenous retrovirus K18-encoded superantigen. J. Clin. Virol. 46:15-19.
43. Wajant H, Scheurich P. 2001. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int. J. Biochem. Cell Biol. 33:19-32.
44. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, and Baldwin AS, Jr. 1998. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683.
45. Ward KN, Gray JJ, Fotheringham MW, Sheldon MJ. 1993. IgG antibodies to human herpesvirus-6 in young children: changes in avidity of antibody correlate with time after infection. J. Med. Virol. 39:131-138.
46. Xuan B, Qian Z, Torigoi E, Yu D. 2009. Human cytomegalovirus protein pUL38 induces ATF4 expression, inhibits persistent JNK phosphorylation, and suppresses endoplasmic reticulum stress-induced cell death. J. Virol. 83:3463-3474.
47. Yamanishi K, et al. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 331:1065-1067.
48. Yao K, et al. 2009. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann. Neurol. 65:257-267.
49. Yi F, et al. 2009. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388:236-247.